Boehringer Ingelheim was also in the news last year with their FDA approval of Pradaxa, an alternative for blood thinning to Warfarin. BD
FDA Approves Pradaxa–An Alternative to Warfarin To Treat Blot Clots Associated With Atrial Fibrillation
Amgen Inc. (NASDAQ: AMGN) and Boehringer Ingelheim today announced they have signed an agreement under which Boehringer Ingelheim will acquire Amgen’s rights in substantially all assets at Amgen’s Fremont California development and manufacturing facility.
The transaction has been approved by the board of managing directors of each company and is expected to close in March of this year. The Amgen Fremont facility currently employs approximately 360 employees and is a state-of-the-art 100,000 square foot manufacturing facility with pilot plant and process development labs.
“With great enthusiasm, we look forward to welcoming the Amgen Fremont employees into the Boehringer Ingelheim family of companies,” said Prof. Dr. Wolfram Carius, Boehringer Ingelheim Board of Managing Directors